Company News
Biocon Launches Yesafili Biosimilar in US
Biocon commercially launched Yesafili™, a biosimilar to Eylea® 2 mg, in the United States on August 3, 2026.
The product is an FDA-approved interchangeable biosimilar for treating serious eye conditio
